Spyre Therapeutics, Inc.
SYRE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $1 | $2 | $19 |
| % Growth | -100% | -62% | -87.6% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $1 | $2 | $19 |
| % Margin | – | 100% | 100% | 100% |
| R&D Expenses | $163 | $90 | $59 | $57 |
| G&A Expenses | $46 | $40 | $29 | $27 |
| SG&A Expenses | $46 | $40 | $29 | $27 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $114 | $0 | $0 |
| Operating Expenses | $209 | $243 | $87 | $84 |
| Operating Income | -$209 | -$242 | -$85 | -$66 |
| % Margin | – | -27,348% | -3,640.2% | -350.3% |
| Other Income/Exp. Net | $1 | -$97 | $1 | -$0 |
| Pre-Tax Income | -$208 | -$339 | -$84 | -$66 |
| Tax Expense | $0 | -$0 | -$0 | $0 |
| Net Income | -$208 | -$339 | -$84 | -$66 |
| % Margin | – | -38,238.1% | -3,598.8% | -351.1% |
| EPS | -3.18 | -46.15 | -24.86 | -25.02 |
| % Growth | 93.1% | -85.6% | 0.6% | – |
| EPS Diluted | -3.18 | -46.15 | -24.86 | -25.02 |
| Weighted Avg Shares Out | 47 | 7 | 3 | 3 |
| Weighted Avg Shares Out Dil | 47 | 7 | 3 | 3 |
| Supplemental Information | – | – | – | – |
| Interest Income | $21 | $6 | $1 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $1 | $2 | $2 |
| EBITDA | -$208 | -$128 | -$83 | -$64 |
| % Margin | – | -14,401.8% | -3,555.9% | -341.9% |